See All Slides - tctmd.com

Slides

Presentation

What is the Best Initial Management Strategy for Stable Ischemic Heart Disease?

Presenter: 218868|Judith Hochman

May 31, 2013

Presentation EuroPCR 2013

One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study

Presenter: 13956|Raul Moreno

May 31, 2013

Presentation EuroPCR 2013

Repositionable Percutaneous Replacement of a Stenotic Aortic Valve through Implantation of the Lotus Valve System

Presenter: 203171|Ian Meredith

May 31, 2013

Presentation EuroPCR 2013

Two-year clinical outcomes in the EVOLVE FHU trial:A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Presenter: 203171|Ian Meredith

May 31, 2013

Presentation

Prognostic Value of Stress CMR Imaging in Patients with Known or Suspected CAD

Presenter: M.J. Lipinski

May 31, 2013

Presentation

Aortic Stenosis in the Elderly: Disease Prevalence and Number of Candidates for TAVR

Presenter: 201433|Ruben L. J. Osnabrugge

May 30, 2013

Presentation

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After TAVI

Presenter: O. Husser

May 29, 2013

Presentation

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

Presenter: M. Urena

May 28, 2013

Presentation

The Impact of Integration of a Multidetector CT Annulus Area Sizing Algorithm on TAVR Outcomes

Presenter: R. K. Binder

May 28, 2013

Presentation EuroPCR 2013

PEPCAD China ISR

Presenter: Run-Lin Gao

May 23, 2013

Advertisement

Slides

What is the Best Initial Management Strategy for Stable Ischemic Heart Disease?

One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study

Repositionable Percutaneous Replacement of a Stenotic Aortic Valve through Implantation of the Lotus Valve System

Two-year clinical outcomes in the EVOLVE FHU trial:A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Prognostic Value of Stress CMR Imaging in Patients with Known or Suspected CAD

Aortic Stenosis in the Elderly: Disease Prevalence and Number of Candidates for TAVR

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After TAVI

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

The Impact of Integration of a Multidetector CT Annulus Area Sizing Algorithm on TAVR Outcomes

PEPCAD China ISR

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content